Deerfield-led $350 mln deal helps launch Aralez Pharmaceuticals
POZEN Inc and Tribute Pharmaceuticals Canada Inc have wrapped up their previously announced merger, creating a new parent company, Aralez Pharmaceuticals Inc (Nasdaq: ARLZ, TSX: ARZ). Headquartered in Canada, Aralez is a pharmaceutical business focused on developing cardiovascular, pain and other specialty therapies. Led by CEO Adrian Adams, it will also have operations in Ireland and the United States. The merger that launched Aralez was supported by up to US$350 million ($486 million) in commitments from a consortium led by U.S. healthcare investment firm Deerfield Management. QLT Inc, Broadfin Capital and JW Asset Management also invested.
5 February 2016•3 mins read
